Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares IssuedShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Ratios

C4 Therapeutics (CCCC) Cash from Financing Activities: 2019-2024

Historic Cash from Financing Activities for C4 Therapeutics (CCCC) over the last 6 years, with Dec 2024 value amounting to $45.3 million.

  • C4 Therapeutics' Cash from Financing Activities fell 26.01% to $7.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $18.3 million, marking a year-over-year decrease of 82.17%. This contributed to the annual value of $45.3 million for FY2024, which is 0.34% down from last year.
  • According to the latest figures from FY2024, C4 Therapeutics' Cash from Financing Activities is $45.3 million, which was down 0.34% from $45.5 million recorded in FY2023.
  • In the past 5 years, C4 Therapeutics' Cash from Financing Activities ranged from a high of $348.9 million in FY2020 and a low of $1.1 million during FY2022.
  • Moreover, its 3-year median value for Cash from Financing Activities was $45.3 million (2024), whereas its average is $30.7 million.
  • Its Cash from Financing Activities has fluctuated over the past 5 years, first soared by 142,904.92% in 2020, then plummeted by 99.33% in 2022.
  • Yearly analysis of 5 years shows C4 Therapeutics' Cash from Financing Activities stood at $348.9 million in 2020, then slumped by 50.88% to $171.4 million in 2021, then slumped by 99.33% to $1.1 million in 2022, then surged by 3,865.91% to $45.5 million in 2023, then dropped by 0.34% to $45.3 million in 2024.